Search Within

Ross Firestone

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (25)
  2. Journal Article (6)
Groups
  1. Department of Medicine (31)
  2. GME, Medicine (31)
  3. Graduate Medical Education (31)
  4. Hematology-Oncology Fellows (31)
  5. Sloan Kettering Institute Postdocs (31)
  6. Weinberg Fellows (31)

More Groups

People
  1. Saad Usmani (31)
  2. Malin Hultcrantz (30)
  3. Kylee Maclachlan (29)
  4. Alexander Lesokhin (28)
  5. Carlyn Rose Tan (28)
  6. David Chung (28)

More People

Years
  1. 2025 (2)
  2. 2024 (21)
  3. 2023 (8)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (13)
  2. Blood (12)
  3. Blood Advances (3)
  4. Journal of Clinical Oncology (2)
  5. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (15)
  2. Elsevier Inc. (13)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (1)

Results (31)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Journal Article

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M. L.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating tumor-intrinsic and patient-specific mechanisms of resistance to teclistamab in anti-BCMA exposed and naïve multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I. S.; Wang, A.; Zhu, M.; Patel, D.; Tan, C.; Hultcrantz, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with del(17p) in newly diagnosed multiple myeloma treated with triplet and daratumumab-based quadruplet induction regimens
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Mailankody, S.; Lahoud, O.; Landau, H.; Chung, D.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save